StockNews.com initiated coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a report released on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Several other research analysts have also commented on CBAY. Piper Sandler reaffirmed a neutral rating and issued a $32.50 price target (down from $33.00) on shares […]
CymaBay Therapeutics (NASDAQ:CBAY) Sees Strong Trading Volume themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) was downgraded by analysts at Raymond James from an “outperform” rating to a “market perform” rating in a research note issued to investors on Tuesday, Briefing.com reports. Several other equities analysts have also issued reports on the company. William Blair reaffirmed a “market perform” rating on shares of […]
Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $25.72 and last traded at $24.89, with a volume of 549844 shares traded. The stock had previously closed at $24.00. Analyst Ratings Changes CBAY has been the subject […]
CymaBay Therapeutics, Inc (NASDAQ:CBAY) General Counsel Sells $117,900 00 in Stock theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.